For Healthcare Professionals Outside the US
Tafinlar + Mekinist is indicated for adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection; for first-line treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation; for adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation.

It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Home > About > BRAF V600+ NSCLC > Treatment Needs

Patients with BRAF V600+ NSCLC may have an aggressive disease

  • BRAF V600+ NSCLC has histological features suggestive of an aggressive tumor1
  • BRAF mutations may be linked to shorter disease-free survival and overall survival compared with patients with wild-type BRAF1

Overall survival based on presence or absence of BRAF V600 mutation1

Chart of overall survival based on presence or absence of BRAF V600 mutation.
border line

TAFINLAR + MEKINIST is an approved targeted treatment for patients with BRAF V600+ NSCLC2,3

border line
A retrospective study to investigate the prevalence, distribution, and prognostic role of BRAF mutations in a large cohort of white patients with NSCLC (N=1046).1
References: 1. Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non–small-cell lung cancer harboring BRAF mutations. J Clin Oncol. 2011;29(26):3574-3579. 2. Tafinlar Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2020. 3. Mekinist Summary of Product Characteristics. Novartis Pharmaceuticals Corp; 2020.

COVID-19 Update


Novartis is closely monitoring the evolving COVID-19 pandemic. For the most recent information on how Novartis is responding, visit the COVID-19 Information Center.

During this time of uncertainty it is important to communicate with your patients about COVID-19 to clarify that they should not stop their treatments except under the direction of the treating physician, and to ensure that patients have sufficient drug to avoid any treatment interruptions.

Reach out to your Novartis representative with any questions related to Novartis products.

04/20  G-ONC-1230566

COMBI-AD was a double-blind, placebo-controlled, Phase 3 trial that compared Tafinlar + Mekinist vs placebo4

ELIGIBILITY REQUIREMENTS

  • Resection of histologically confirmed Stage IIIA, B, or C with BRAF V600E or BRAF V600K mutation
  • ECOG performance status ≤1
  • No prior systemic anticancer treatment or radiotherapy for melanoma
TAFINLAR 150 mg BID + MEKINIST
2 mg QD (n=438)
imgh22

Placebo (n=432)

STUDY ENDPOINTS

  • Primary endpoint was RFS
  • Secondary endpoints were OS, distant metastasis-free survival, freedom from relapse, and safety
COMBI-d phase 3 study: Tafinlar® (dabrafenib) + Mekinist® (trametinib) vs Tafinlar® monotherapy